TCI Gene

TCI Gene FCF Yield

The Free Cash Flow Yield of TCI Gene (6879.TWO) as of Nov 3, 2026 is 15.29 %. In the previous year, Free Cash Flow Yield was 5.50 % — a change of 177.91% (higher).

FCF Yield

15.29 %

YoY

177.91%

Last updated:

Free Cash Flow Yield of TCI Gene is 2025 15.29 % . Free Cash Flow Yield of TCI Gene was 2024 5.50 % . It decreases by 177.91% higher compared to the previous year.

The TCI Gene FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2019
8.90 TWD
Jan 1, 2020
3.21 TWD
Jan 1, 2021
9.70 TWD
Jan 1, 2022
9.63 TWD
Jan 1, 2023
1.49 TWD
Jan 1, 2024
5.50 TWD
Jan 1, 2025
15.29 TWD
The TCI Gene FCF Yield history
YEARFCF YieldYoY
15.29 %+177.91%
5.50 %+269.83%
1.49 %-84.55%
9.63 %-0.73%
9.70 %+201.89%
3.21 %-63.87%
8.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TCI Gene Stock analysis

What does TCI Gene do? TCI GENE, Inc. generates revenue through genetic testing services, virus testing services, and cell experiment services. The company produces adipose-derived stem cell preparations for degenerative arthritis and knee cartilage defects, as well as natural killer cell preparations for solid cancer treatment. Personalized genetic health food is also a key product. These offerings are primarily sold within Taiwan, targeting consumers interested in disease risk assessment, drug genetic testing, and personalized health solutions. The firm's comprehensive genetic testing covers areas like child growth, youth beauty, weight management, and cardiovascular drug responses, while pharmacogenetic testing addresses depression and insomnia. The company's product portfolio includes specialized services such as youth beauty genetic testing and anti-aging genetic testing, which appeal to wellness-focused segments. Adipose-derived stem cell preparations are marketed for orthopedic applications, and natural killer cell preparations target cancer patients seeking alternative therapies. Personalized genetic health food is positioned for consumers seeking tailored nutritional support based on genetic profiles. All products are distributed exclusively in Taiwan, with no international market presence mentioned. TCI GENE, Inc. serves customers seeking preventive health management through genetic insights. The primary buyers are individuals in Taiwan interested in disease risk prediction, drug response optimization, and personalized wellness. The firm's focus on genetic health food and cell-based treatments targets health-conscious consumers and patients requiring specialized medical solutions. Sales are concentrated within Taiwan, reflecting the company's localized market strategy. TCI Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TCI Gene stock

Free Cash Flow Yield of TCI Gene is 15.29 % in 2025.

Free Cash Flow Yield of TCI Gene changed from 5.50 % to 15.29 %, representing a 177.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield TCI Gene since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's TCI Gene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — TCI Gene

All Key Metrics — TCI Gene